maintain the high level Balanced News


      News Sentiment: +1.0 (Past 200 Days)

How To Interpret

Protection Against Severe SARS-CoV-2 Infection (Including Hospitalization) Markedly Wanes with 3rd Booster Dose of Pfizer mRNA COVID-19 Vaccine

Diseases and Conditions

A Pfizer-funded study demonstrates durability challenges with the mRNA vaccine called BNT162b2. Originally developed by the German biotech BioNTech, Pfizer entered a strategic alliance to co-develop and co-commercialize the advanced mRNA-based COVID-19 vaccine. A dynamic, mutating mucosal pathogen, SARS-CoV-2 variants have become more evasive to COVID-19 variants of concern, starting last summer with Delta, and then more recently Omicron and BA.2, a subvariant. Recently, Dr. Sara Y. Tartoff affiliated with a major California-based health system known as Kaiser Permanente Southern California led a study demonstrating that while BNT162b2 confers high protection against hospital and emergency department admission for three months, even with a third booster dose thereafter, performance wanes against the pervasive Omicron variant. This is bad news as the core value proposition of this vaccine is that it confers high levels of protection against more severe COVID-19 infection, hospitalization, and even death, for lengthier periods of time. A bombshell finding, the investigators from Kaiser’s Department of Research & Education recommend “doses of current, adapted, or novel COVID-19 vaccines might be needed to maintain high levels of protection” against future COVID-19 surges. Recently, Dr. Paul Marks of the Food and Drug Administration (FDA) went on the record in an interview that continuous boosts aren’t good and that a next-generation vaccine isn’t likely until 2023 or beyond.
Trial Site News     Apr 24, 2022